Clinical Trial Update: Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and activity of G-202 in PSMA-expressing clear cell renal cell carcinoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• G-202

Snippet

Sponsor: GenSpera, Inc. | Conditions: Clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED